Impact of pramlintide on glucose fluctuations and postprandial glucose, glucagon, and triglyceride excursions among patients with type 1 diabetes intensively treated with insulin pumps

Diabetes Care

Volumn 26, Issue 1, 2003, Pages 1-8

  Levetan, Claresa ^a   Want, Laura L ^a   Weyer, Christian ^b   Strobel, Susan A ^b   Crean, John ^b   Wang, Yan ^b   Maggs, David G ^b   Kolterman, Orville G ^b   Chandran, Manju ^c   Mudaliar, Sunder R ^c   Henry, Robert R ^c  

^a MedStar Clinical Research Center   (United States)

^b AMYLIN PHARMACEUTICALS INC   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCAGON; GLUCOSE; HEMOGLOBIN A1C; INSULIN; INSULIN LISPRO; PRAMLINTIDE; TRIACYLGLYCEROL;

ADULT; AREA UNDER THE CURVE; ARTICLE; BOLUS INJECTION; CLINICAL ARTICLE; CLINICAL TRIAL; CONTINUOUS GLUCOSE MONITORING SYSTEM; CONTINUOUS INFUSION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG MECHANISM; FEMALE; GLUCAGON BLOOD LEVEL; GLUCOSE BLOOD LEVEL; HUMAN; HYPOGLYCEMIA; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN INFUSION; INSULIN PUMP; INSULIN TREATMENT; MALE; NAUSEA; PERSONAL MONITORING; RANDOMIZED CONTROLLED TRIAL; TRIACYLGLYCEROL BLOOD LEVEL;

ADULT; AMYLOID; BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 1; FEMALE; FRUCTOSAMINE; GLUCAGON; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; INSULIN INFUSION SYSTEMS; MALE; MIDDLE AGED; POSTPRANDIAL PERIOD; TRIGLYCERIDES;

EID: 0038815070     PISSN: 01495992     EISSN: None     Source Type: Journal    
DOI: 10.2337/diacare.26.1.1     Document Type: Article

References (26)

1. Klein R, Klein BE, Moss SE, Cruickshanks KJ: The medical management of hyperglycemia over a 10-year period in people with diabetes. Diabetes Care 19:744-750, 1996
2. Boland E, Monsod T, Delucia M, Brandt CA, Fernando S, Tamborlane WV: Limitations of conventional methods of self-monitoring of blood glucose: lessons learned from 3 days of continuous glucose sensing in pediatric patients with type 1 diabetes. Diabetes Care 24:1858-1862, 2001
3. Rizza RA, Gerich JE, Haymond MW, Westland RE, Hall LD, Clemens AH, Service FJ: Control of blood sugar in insulin-dependent diabetes: comparison of artificial endocrine pancreas, continuous subcutaneous insulin infusion and intensified conventional insulin therapy. N Engl J Med 303:1313-1318, 1980
4. Hirsch IB: Hypoglycemia and the hypoglycemic unawareness syndrome. Diabetes Technol Ther 2 (Suppl. 1):S81-S87, 2000
5. Kaufman FR, Gibson LC, Halvorson M, Carpenter S, Fisher LK, Pitukcheewanont P: A pilot study of the continuous glucose monitoring system: clinical decisions and glycemic control after its use in pediatric type 1 diabetic subjects. Diabetes Care 24:2030-2034, 2001
6. Kruger D, Marcus AO: Psychological motivation and patient education: a role for continuous glucose monitoring. Diabetes Technol Ther 2 (Suppl. 1):S93-S97, 2000
7. Bode BW, Hirsch IB: Using the continuous glucose monitoring system to improve the management of type 1 diabetes. Diabetes Technol Ther 2 (Suppl. 1):S43-S48, 2000
8. The DCCT Research Group: The relationship of glycemic exposure (HbA1c) to the risk of development and progression of retinopathy in the Diabetes Control and Complications Trial. Diabetes 44:968-983, 1995
9. Jacobson AM: The psychological care of patients with insulin-dependent diabetes mellitus. N Engl J Med 334:1249-1253, 1996
10. Edelman SV, Weyer C: Unresolved challenges with insulin therapy in type 1 and type 2 diabetes: potential benefit of replacing amylin, a second β-cell hormone. Diabetes Technol Ther 4:175-189, 2002
11. Weyer C, Maggs DG, Young AA, Kolterman OG: Amylin replacement with pramlintide as an adjunct to insulin therapy in type 1 and type 2 diabetes mellitus: a physiological approach toward improved metabolic control. Curr Pharm Des 7:1353-1373, 2001
12. Nyholm B, Brock B, Orskov L, Schmitz O: Amylin receptor agonists: a novel pharmacological approach in the management of insulin-treated diabetes mellitus. Expert Opin Investig Drugs 10:1641-1652, 2001
13. Young A: Amylin's physiology and its role in diabetes. Curr Opin Endocrinol Diabetes 4:282-290, 1997
14. Buse JB, Weyer C, Maggs DG: Amylin replacement with pramlintide in type 1 and type 2 diabetes: a physiological approach to overcome barriers with insulin therapy. Clinical Diabetes 20:137-144, 2002
15. Gedulin BR, Rink TJ, Young AA: Dose-response for glucagonostatic effect of amylin in rats. Metabolism 46:67-70, 1997
16. Young AA, Gedulin B, Vine W, Percy A, Rink TJ: Gastric emptying is accelerated in diabetic BB rats and is slowed by subcutaneous injections of amylin. Diabetologia 38:642-648, 1995
17. Nyholm B, Orskov L, Hove KY, Gravholt CH, Moller N, Alberti KG, Moyses C, Kolterman O, Schmitz O: The amylin analog pramlintide improves glycemic control and reduces postprandial glucagon concentrations in patients with type 1 diabetes mellitus. Metabolism 48:935-941, 1999
18. Fineman M, Koda JE, Weyer C, Shen LZ, Strobel SA, Maggs D, Kolterman O: The human amylin analogue pramlintide corrects postprandial hyperglucagonemia in patients with type I diabetes. Metabolism 51:636-641, 2002
19. Kong MF, Stubbs TA, King P, Macdonald IA, Lambourne JE, Blackshaw PE, Perkins AC, Tattersall RB: The effect of single doses of pramlintide on gastric emptying of two meals in men with IDDM. Diabetologia 41:577-583, 1998
20. Thompson RG, Peterson J, Gottlieb A, Mullane J: Effects of pramlintide, an analog of human amylin, on plasma glucose profiles in patients with IDDM: Results of a multicenter trial. Diabetes 46:632-636, 1997
21. Whitehouse F, Kruger DF, Fineman M, Shen L, Ruggles JA, Maggs DG, Weyer C, Kolterman OG: A randomized study and open-label extension evaluating the long-term efficacy of pramlintide as an adjunct to insulin therapy in type 1 diabetes. Diabetes Care 25:724-730, 2002
22. Maggs D, Fineman M, Burrell T, Gottlieb A, Kolterman OG: In type 1 diabetes, addition of pramlintide to insulin therapy resulted in long-term glycemic improvement without the increase in severe hypoglycemia noted in patients treated with insulin alone (Abstract). Diabetes 50: A442, 2001
23. Gottlieb A, Velte M, Fineman M, Kolterman O: Pramlintide as an adjunct to insulin therapy improved glycemic and weight control in people with type 1 diabetes during treatment for 52 weeks (Abstract). Diabetes 49:A109, 2000
24. Dinneen S, Alzaid A, Turk D, Rizza R: Failure of glucagon suppression contributes to postprandial hyperglycaemia in IDDM. Diabetologia 38:337-343, 1995
25. Georgopoulos A: Postprandial triglyceride metabolism in diabetes mellitus. Clin Cardiol 22 (Suppl. 6):1128-1133, 1999
26. Patsch JR, Hopferwieser T, Miesenboeck G, Muehlberger V, Knapp E, Dunn JK, Gotto AM Jr, Patsch W: The relationship of triglyceride metabolism and coromary artery disease: studies in the postprandial state. Arterioscler Thromb 12:1336-1345, 1992